Labcorp to acquire Opko Health BioReference assets for up to $872 million
Laboratory operator Labcorp announced it will purchase select assets from Opko Health's BioReference Health subsidiary for $722 million in cash, with an additional potential payment of up to $150 million tied to revenue from a prostate cancer test. Opko Health shares surged 20% in premarket trading following the announcement.
